Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Background Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute
myeloid leukaemia characterised by the presence of the PML–RARA fusion transcript. The …

Despite major improvements in outcome over the past decades, acute myeloid leukemia
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …

Historically, acute promyelocytic leukemia (APL) was considered to be one of the most fatal
forms of acute leukemia with poor outcomes before the introduction of the vitamin A …

The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO)
into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management …

Although acute promyelocytic leukemia (APL) is one of the most characterized forms of
acute myeloid leukemia (AML), the molecular mechanisms involved in the development and …

Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …

The incidence of early death in a large population of unselected patients with acute
promyelocytic leukemia (APL) remains unknown because of the paucity of outcome data …

Preliminary independent reports of the Italian GIMEMA and the Spanish PETHEMA trials for
newly diagnosed acute promyelocytic leukemia (APL) indicated a similarly high …